This website uses cookies to enhance your browsing experience, improve site performance, and gather analytics. By selecting 'Accept,' you consent to these cookies as described in our Privacy Policy.

Logo

Nashville Early Diagnosis Lung Cancer Project

Sponsored by Vanderbilt-Ingram Cancer Center

About this trial

Last updated 2 years ago

Study ID

VICC THO 1078

Status

Active not recruiting

Type

Observational

Placebo

No

Accepting

55 to 80 Years
All Sexes

Trial Timing

Started 15 years ago

What is this trial about?

This screening study will address the lack of molecular strategies for the early detection of lung cancer and integrate those with epidemiological and imaging strategies. The hypothesis is that the repeated measure of biomarkers of risk obtained from the molecular analysis of biological specimens including those from bronchoscopy (bronchial brushings and biopsies) may contribute to the refinement of high-risk populations and allow an earlier clinical diagnosis. The goal of the investigators study is to provide screening for lung cancer in a high-risk population. In this prospective cohort it will be tested whether repeated measure of biomarkers of risk allows early detection of lung cancer.

What are the participation requirements?

Inclusion Criteria

* 55 - 80 years of age

* Current smoker or former smoker. If former smoker, must have quit smoking less than 15 years ago

* >/= 30 pack year of smoking history

Exclusion Criteria

* History of diagnosis/treatment of lung cancer in the past 2 years

* History of head/neck or esophageal cancer in the last 1 year

* Inability to provide informed consent

* Participants in whom stopping anti-platelet or anti-coagulation therapy would have an adverse effect (DVT, mechanical heart valves, unstable coronary syndrome, etc.)